Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus

NCT02554019 is registered in ClinicalTrials.gov with Biotest as lead sponsor.

NCT NCT02554019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02554019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Biotest
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2015
Completion date
October 25, 2017
Enrollment
36 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus